On July 31, Moderna, Inc. fell 5.04% in pre-market trading, trading at $54.42 per share, with turnover of $2.5282 million. The company released its second-quarter earnings report before market open, triggering a shift toward cautious sentiment among investors.

On the news front, Bank of America maintained its underperform rating on the stock, noting that Moderna's Q2 results would face increased scrutiny given the stock's prior outperformance. While multiple Wall Street institutions had recently raised their target prices — Goldman Sachs to $67, Piper Sandler to $77, and Jefferies to $60 — overall market consensus remains conservative. FactSet's mean analyst target price stands at just $52.16, reflecting persistent skepticism about near-term revenue recovery and profit margin improvement. Analysts have cited concerns over inventory and capacity utilization impacts on unit costs, limited expense reduction potential, and uncertainty around new product commercialization timelines.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)